|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.5500 - 3.7300|
|52 Week Range||0.9500 - 4.2500|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, today announced that it has been officially granted a CBD Processor Research Partner Authorization by the New York State Department of Agriculture and Markets. The Department promotes New York agriculture and its high-quality and diverse products, fosters agricultural environmental stewardship, and safeguards the State’s food supply, land, and livestock to ensure the viability and growth of New York’s agriculture industries.
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, today announced that they have partnered with Cambrian Alliance (CA), one of the largest buying groups for independent pharmacies in the United Kingdom. The partnership allows CA members to access Elixinol brand products, an exclusive launch offer package, point of sale material and staff training. “We are delighted to work in partnership with Elixinol, providing our members with access to a new range of products,” said Nathan Wiltshire, CEO of Cambrian Alliance.
It's become trendy for stock "gurus" to start pushing marijuana stocks. A few months ago, most of them were silent on the issue. Now they all seem to be pounding the table.I urged people to consider cannabis stocks back in 2014 - for one simple reason: Colorado had opened the door by being the first U.S. state to legalize recreational marijuana.Since then, Colorado has made over $6 billion in legal marijuana sales in just four years. This has produced more than $927 million in tax revenue. Some of the biggest names in U.S. legal cannabis operate there, like Charlotte's Web (OTCMKTS:CWBHF) and Elixinol Global (OTCMKTS:ELLXF), and they are flourishing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFrom the beginning, I knew that was just the first "domino" to fall… leading to full, federal legalization.Given that we've been under marijuana prohibition for generations, many folks are still skeptical. Well, based on the facts, news, and trends - not a gut feeling for or against marijuana - I do expect legalization, and soon. And I've got six reasons why. * 7 Dangerous Dividend Stocks to Stay Far Away From Catalyst 1: SAFE Banking Act & STATES ActThe first official step to full-blown legalization will likely be one of two specific bills that are working their way through Congress.In March, the Secure and Fair Enforcement (SAFE) Banking Act passed the U.S. House Committee on Financial Services with bipartisan support. If passed, the bill will allow banks to work with marijuana companies without fear of breaking any laws.Only a small number of regional banks and credit unions currently take the risk of offering services to the industry. Banking costs for marijuana companies are exceptionally high - try $5,000 a month maintenance fees! - due to the risk banks are taking by technically breaking federal laws. So, access to traditional banks/loans would be a game-changer.The other piece of legislation, the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, will allow individual states to make their own laws on cannabis, including banking. Any bank lawfully working with marijuana businesses will be protected under the STATES Act.At least one of these bills will likely be passed in the coming months, and possibly both. Either would be a major step toward legalizing marijuana in the United States. Catalyst 2: The 2020 ElectionNote: Please understand that my analysis on politics and the stock market is 100% from an investing point of view. I have no desire to push any type of politics on you in any manner. I hate it when other people do that to me, and I would never do it to you. My one and only goal is to make you money.The 2020 presidential election is already in the daily headlines. I've lost track of the number of Democrats that have thrown their hats into the ring. I know it's more than 20… and the election is still more than a year-and-a-half away!These candidates come from all types of backgrounds. Some are far left and others are more moderate. The candidates will undoubtedly take vicious shots at each other as they try to secure the Democratic nomination, but there is one topic that could create that kumbaya moment - marijuana.Nearly every Democratic candidate has called for legalization of even recreational marijuana as well expunging federal charges related to cannabis. Former Vice President Joe Biden is one major exception, but I don't think we've heard the last from him on this issue. Expect the topic to be at the forefront of town halls and debates over the next 18 months.In the meantime, several bills were introduced in the last year that would legalize marijuana nationwide. The one that has the best chance - and the backing of big-name Democrats - is the Marijuana Justice Act. It was originally introduced in 2017, but a vote never took place. New Jersey Senator Cory Booker reintroduced the bill in February. Its chances of getting through the Senate are very low, but the bill does put pressure on the Republicans up for re-election. That brings me to the next catalyst… Catalyst 3: President TrumpI have attended a few cannabis conferences recently, and I stay in touch with industry insiders. In just the last few months, I've noticed a significant increase in the number of insiders who expect President Trump to introduce a bill to legalize marijuana. Based on what I'm hearing from them and people who have connections in D.C., the odds of the president introducing such a bill are now well above 50%.We know President Trump wants another term, and according to a poll by Civilized, cannabis users plan to vote come November 3, 2020. Civilized is a pro legalization site, but about 90% of people surveyed said they intend to vote in the next presidential election. That's significant, and about 3% higher than non-cannabis consumers.Democrats will make sure marijuana is front and center in all debates. And it makes sense politically for Republicans, too. Backing marijuana's legalization will not hurt the party's voter base and could bring some moderates over to their side.That is where President Trump comes into play. If legalizing marijuana can swing some moderate Democrats to his side, he will not hesitate. I and others I talk with increasingly believe President Trump will strike preemptively and legalize marijuana before the election. Catalyst 4: The DEAMarijuana remains a Schedule 1 drug in the United States, which is one reason it is illegal. According to the Drug Enforcement Administration (DEA), Schedule 1 drugs are generally unsafe with a high potential for abuse and no accepted medical use.More and more studies refute all three of those criteria when it comes to marijuana. The last qualifier - no accepted medical use - is now known to be simply false.What will it take for the DEA to remove marijuana from Schedule 1? Well, the first thing is old-fashioned common sense. Heroin, LSD, and ecstasy are all Schedule 2 drugs, which in theory means they are less dangerous than marijuana. That's crazy. You don't need a medical or biology degree to see how out of touch and outdated that is.Beyond common sense, there are other things that will force the DEA to change marijuana's classification. The most likely are more studies demonstrating the positive medicinal effects of marijuana.This is yet another silly situation because government regulations make it extremely difficult to perform those studies. However, new Attorney General William Barr has said he supports more marijuana research, and the more individual states do, the higher the likelihood this will change.The bottom line is that the DEA's blessing is necessary for marijuana to be legalized. If all other parties, including Congress and President Trump, get behind legalization, the DEA will have no choice but to succumb to the pressure. Catalyst 5: The Farm BillSomething called the Farm Bill doesn't sound all that exciting, but believe me, it is. The bill legalized hemp in the United States for the first time in over 80 years.To be clear, the legalization of hemp did not have any direct effect on marijuana laws. But it did open up the conversation of doing the same thing with cannabis, which is important. If the Farm Bill was a test run of legalization, the government should be satisfied.We're already seeing demand for hemp-related goods. Products that include cannabidiol (CBD), the non-psychoactive part of the plant, are now found in food, drinks, skincare products, etc. What's more, they are available at places like CVS Health (NYSE:CVS), Walgreens (NASDAQ:WBA), and Bed, Bath & Beyond (NASDAQ:BBBY). The hemp-CBD market is expected to balloon 40X over the next few years. Catalyst 6: Money, Money, MoneyGood or bad, right or wrong, many decisions are made based on money. When it comes to marijuana, the dollar signs are too big to ignore.The amount of tax revenue that states could generate from legal marijuana is impressive. And when politicians of one state watch neighboring states bring in revenue, it puts pressure on them to get in on the action. Thus, the snowball effect of more states legalizing marijuana.Job creation is an often overlooked benefit of legalization. One study shows that marijuana could result in over 300,000 new jobs by 2020.California has already created 80,000 jobs in the marijuana industry, according to a study from ICF International. To put that into money terms - that is a $3.5 billion increase in labor income. And guess what? More income taxes as well.All states would love to have hundreds of millions in additional revenue. So would the federal government… which is a big reason for the bold prediction I'm making now.The United States is flying towards legalization, which means U.S. pot stocks have massive potential ahead. As an investor, you need to grab your slice of that pie. However you feel about marijuana, numbers don't lie, and getting in on the ground floor of a mega-trend like this is how you build explosive wealth.But it's critical to get in BEFORE America legalizes nationally.Marijuana stocks are about to deliver their next wave of wealth much quicker than you'd think. Click here for my presentation on the topic.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dangerous Dividend Stocks to Stay Far Away From * 7 Tips for New Investors Young and Old * 10 Great Stocks to Buy on Dips Compare Brokers The post 6 Signs That Marijuana Legalization is Closer Than You Think appeared first on InvestorPlace.
Last week, Elixinol (OTC: ELLXF) snapped up a 25-percent stake in Altmeds, a company that makes CBD products for pets. Although some folks might dismiss the market for CBD-based pet products, it’s actually quite lucrative. Certainly this is the case with Altmeds, and will likely be the case with other producers of cannabis-based pet products.
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, today announced that they have purchased a 25 percent stake in Altmeds LLC, maker of the pioneering and market leading Pet Releaf hemp-derived CBD pet line. Pet Releaf hemp-derived CBD topical, edibles and oils for pets currently sell in over 4,000 independent pet stores throughout the USA and multiple international markets. “Pet Releaf and Elixinol share the same values in sourcing and end-product superiority,” said Stephen Smith, President and Co-Founder of Pet Releaf.
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, announces its latest product in partnership with Ken Brown, MD of KBMD Health, KBMD CBD Extract in Elixinol’s signature Natural and Cinnamint flavors. Created in partnership with Dr. Brown, an established physician specializing in gastroenterology, this full-spectrum product contains 900mg of CBD in a 1oz tincture, and is intended to help promote abdominal health and support relief from discomfort in those impacted by digestive issues. Passionate about bridging the gap between natural and medical science, Dr. Brown has been utilizing Elixinol hemp CBD extract for over two years in his own gastroenterology practice to support the digestive wellness of hundreds of patients.
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, today announced that it has received U.S. Hemp Authority™ Certification. The prestigious certification has only been granted to a total of 14 companies to date, and grants Elixinol the ability to use the Certified Seal of the U.S. Hemp Authority on all hemp product packaging and marketing materials. The U.S. Hemp Authority Certification Program is the hemp industry’s initiative to provide high standards, best practices, and self-regulation, in an effort to give confidence to consumers and law enforcement that hemp products are safe and legal.
DENVER, April 12, 2019 -- Elixinol Global Limited (EXL or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp, dietary supplements and.
Charlotte's Web Holdings Inc. and Elixinol Global Ltd. are pioneers in hemp/CBD. Elixinol, the fastest over the second half of 2018, has new, cutting-edge products and a lower relative valuation. Charlotte's Web's Q4 sales rebounded after a hiccup in Q3 and had solid Q/Q sales growth of 21%.
DENVER, March 18, 2019 -- Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, announces a new take on a.
OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ -- OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, announces its latest product innovation, Create | Build | Dream (C | B | D), a full-spectrum water-soluble hemp CBD powder. “Our CBD powders are all-natural, taste great and mix well with beverages, no matter the time of day,” said Chris Husong, Elixinol’s Sales & Marketing Director.
OTCQX: ELLXF), has expanded its EU operations with key personnel hires and offices in the Netherlands, Spain, and the United Kingdom. The appointments are accompanied by a new go-to-market strategy and key initiatives including the launch of new e-commerce capabilities, sales hubs, with 12 full-time sales and marketing employees, in the Netherlands, Spain, and the United Kingdom aimed at capturing the European cannabis market opportunity, which analysts expect will be worth more than $130 billion in annual sales by 2028 (in today’s dollars).
SAN FRANCISCO, Feb. 05, 2019 -- Fincom Investment Partners discusses Elixinol Global Ltd.'s (EXL:ASX; ELLXF:OTCQX) Q4 earnings, and the hemp/CBD field. Company mentioned:.
Leading global hemp CBD company Elixinol, has announced its entry into the New Zealand marketplace, offering its comprehensive range of cannabidiol (CBD) products to the NZ public on a prescription basis via the elixinol.com website. OTCQX: ELLXF) and has launched in New Zealand following the December 2018 passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act.
The announcement comes on the heels of the December 2018 passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act which classifies CBD, with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug. Individual patients may now import up to a 3-month supply of CBD products, provided those products meet prescription medicine guidelines. Medicinal practitioners, pharmacies may also import and sell CBD products as can individuals or companies holding a license to sell medicines in New Zealand.
OTC: ELLXF), announces Joy Beckerman’s appointment to Elixinol’s team starting January 1, 2019. In Beckerman’s role as Regulatory Officer and Industry Liaison, she will advise Elixinol’s executive team on the industry’s changes and ensure Elixinol’s practices continue to meet or exceed the requirements of hemp’s dynamic regulatory framework following the 2018 Farm Bill which federally legalized hemp.
Paul Benhaim launched one of the most successful CBD companies in the world, but he's putting some of the riches from that venture back into hemp plastics — a bygone dream made possible by the farm bill.
SAN FRANCISCO, Dec. 18, 2018 -- The U.S. Congress passed the 2018 Farm Bill that legalizes hemp; the bill is expected to be signed by the President soon. Against this backdrop,.
The 2018 Farm Bill was passed by the Senate on Tuesday by a vote of 87-13. The next move is that the legislation heads to the House for a vote -- and then if it passes there, it goes to President Trump to be signed into law. The impact of this legislation on the cannabis industry is enormous.
DENVER, Dec. 11, 2018 -- US-based Elixinol announces the distribution of its first globally available, all-natural, hemp-based skin care and hair care line, Sativa. The 8.
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Elixinol Global Limited (ELLXF), a global presence in the cannabis industry including hemp-derived CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. The Company is closely monitoring ongoing 2018 Farm Bill legislative changes in the US which, if passed will strengthen the Elixinol USA business considerably and open up its ability to trade nationally and accelerate growth. The management expects growth in the Hemp Foods Australia business to be supported by launches of the company's own finished food products and penetration in the cosmetics segment through its SATIVA Skincare range.
OTCQX: ELLXF), achieved a milestone in the U.S. by reporting retail sales approaching seven figures over the Thanksgiving shopping holiday. The record revenue was buoyed by increased U.S. consumer demand and Elixinol’s annual U.S. “Buy One Get One” promotion over the U.S. Thanksgiving holiday shopping weekend. 5% of all elixinol.com sales are donated to charity benefiting veterans and various health organizations. “I co-founded this business with a global vision to give everyone, from individuals to organizations, the opportunity to enjoy hemp’s restorative benefits,” said Paul Benhaim, Elixinol Global CEO and Elixinol co-founder.
As the industry impatiently awaits passage of the 2018 Farm Bill and pending removal of hemp from the Controlled Substances Act, companies are quickly moving to position themselves as leading suppliers of hemp-based CBD products, and investors are all too happy to help foot the bill. Two companies that have been particularly aggressive in their pursuit of the hemp-based CBD market have been Elixinol Global Ltd. (OTCQX: ELLXF) and MariMed, Inc. (OTCQB:MRMD). Shares for the IPO were sold at $1.00 AUD per share ($0.73 USD), but the stock quickly climbed to $1.82 AUD ($1.32 USD) within the first week of trading.